Biomarkers and New Drug Targets

Biomarker are defined as these are the biological characteristic that is objectively measured and they are evaluated as an indicator of the normal biological or the pathological processes, or a response to a therapeutic intervention. Biomarkers are also important in the development of the new drug therapies through the discovery of "druggable targets." In addition to the identifying of drug targets, the biomarkers have the potential to speed development of the new disease therapies through the use of "progression" markers to delineate the development and the course of a disease. Researchers can also use the changes in the progression markers to understand and how a new therapy is successfully slowing – or even reversing – the disease process. Results of the studies like these will allow researchers to focus on the efforts and resources on the most effective therapies, thus reducing the time and the cost to bring a new therapy to the market and eventually to the patient.

  • Biomarker and Drug Target Validation
  • Image Documentation and In Situ Visualization
  • Biomarker Assay Development

Related Conference of Biomarkers and New Drug Targets

September 14-15, 2026

6th International Conference on Pharmaceutical Chemistry

Paris, France
September 24-25, 2026

6th World Congress on Rare Diseases & Orphan Drugs

Paris, France
November 26-27, 2026

5th World Conference on Pharma Industry and Medical Devices

Zurich, Switzerland
November 26-27, 2026

5th World Congress on Precision and Personalized Medicine

Zurich, Switzerland
December 14-15, 2026

5th Global Summit on Pharmaceutical Research

Paris, France
January 26-27, 2027

22nd Annual Meet on Pharmaceutical Sciences

Paris, France
April 27-28, 2027

10th European Biopharma Congress

Paris, France

Biomarkers and New Drug Targets Conference Speakers

    Recommended Sessions

    Related Journals

    Are you interested in